Lexeo Therapeutics, Inc. Common Stock (LXEO) vs TriSalus Life Sciences, Inc. (TLSI)
A side-by-side comparison of Lexeo Therapeutics, Inc. Common Stock and TriSalus Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TLSI
TriSalus Life Sciences, Inc.
$4.27HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LXEO vs TLSI
growth of $100 · dividends reinvested · last 3yLXEO -66.1% (-30.3%/yr)TLSI -5.6% (-1.9%/yr)TLSI compounded faster over this window
LXEO TLSI
LXEO vs TLSI: by the numbers
- •TLSI is the larger company ($263M vs $259M market cap).
- •Both run net losses; LXEO's is the smaller (0.00% vs -62.59% net margin).
Metrics side by side
Valuation
| Metric | LXEO | TLSI |
|---|---|---|
| P/S ratio | N/A | 5.83 |
| P/B ratio | 1.10 | 40.14 |
Profitability
| Metric | LXEO | TLSI |
|---|---|---|
| Gross margin | 0.00% | 85.79% |
| Operating margin | 0.00% | -59.68% |
| Net margin | 0.00% | -62.59% |
| ROE | -37.12% | -430.72% |
| ROIC | -39.76% | -59.50% |
Growth (annualized)
| Metric | LXEO | TLSI |
|---|---|---|
| Total return CAGR (5Y) | N/A | -15.05% |
Go deeper
Dig into the metrics
Lexeo Therapeutics, Inc. Common Stock ROETriSalus Life Sciences ROELexeo Therapeutics, Inc. Common Stock operating marginTriSalus Life Sciences operating marginLexeo Therapeutics, Inc. Common Stock revenue growthTriSalus Life Sciences revenue growthLexeo Therapeutics, Inc. Common Stock free cash flowTriSalus Life Sciences free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.